Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Edwards Lifesciences (NYSE:EW) had its price objective hoisted by equities researchers at Deutsche Bank Aktiengesellschaft from $85.00 to $94.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 17.62% from the stock’s current price.

Several other analysts also recently weighed in on EW. Argus upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Evercore ISI increased their target price on Edwards Lifesciences from $73.00 to $77.00 and gave the stock an “in-line” rating in a report on Tuesday, July 8th. Citigroup reiterated a “buy” rating and issued a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Morgan Stanley raised their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Finally, Mizuho lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $79.92 on Friday. The business’s 50-day moving average price is $76.58 and its two-hundred day moving average price is $73.56. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. Edwards Lifesciences has a one year low of $59.41 and a one year high of $83.00. The company has a market capitalization of $46.88 billion, a P/E ratio of 11.50, a price-to-earnings-growth ratio of 4.02 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. Analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 5,980 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the transaction, the chief executive officer owned 58,284 shares of the company’s stock, valued at $4,366,054.44. The trade was a 9.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president owned 50,356 shares of the company’s stock, valued at approximately $3,897,554.40. This represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,848 shares of company stock valued at $2,314,488. 1.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in the stock. NorthRock Partners LLC boosted its stake in shares of Edwards Lifesciences by 13.2% in the second quarter. NorthRock Partners LLC now owns 22,705 shares of the medical research company’s stock valued at $1,776,000 after buying an additional 2,650 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Edwards Lifesciences by 12.6% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 26,461 shares of the medical research company’s stock worth $2,069,000 after purchasing an additional 2,966 shares in the last quarter. MGO One Seven LLC increased its holdings in Edwards Lifesciences by 9.1% in the second quarter. MGO One Seven LLC now owns 7,266 shares of the medical research company’s stock valued at $568,000 after purchasing an additional 604 shares during the period. LRI Investments LLC increased its holdings in Edwards Lifesciences by 1.0% in the second quarter. LRI Investments LLC now owns 14,971 shares of the medical research company’s stock valued at $1,171,000 after purchasing an additional 147 shares during the period. Finally, CWM LLC increased its holdings in Edwards Lifesciences by 24.1% in the second quarter. CWM LLC now owns 40,851 shares of the medical research company’s stock valued at $3,195,000 after purchasing an additional 7,935 shares during the period. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.